12:00 AM
 | 
Sep 29, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Pollinex Quattro Ragweed: Phase III data

The North American Phase III R301 trial showed that Pollinex Quattro Ragweed vaccine met the primary endpoint of difference in combined symptom/medication score vs. placebo over the 4 peak pollen weeks. Vaccinated patients in the per protocol population had a 12% improvement vs. placebo (n=381 patients; p=0.0478). The trial enrolled 993 patients....

Read the full 240 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >